FDA Greenlights First At-Home Cervical Cancer Test—A Global Game Changer

The newly approved HerTest kit empowers women to screen for HPV (the leading cervical cancer cause) privately at home. The $35 device:

🩺 Collects samples with 99% clinic-level accuracy
📱 Syncs results to a secure app with telehealth options
🌎 Could prevent 300,000+ deaths annually in low-access regions

“This democratizes women’s health,” says OB-GYN Dr. Priya Kapoor. Rolling out in Q4 2023, it’s already being adapted for other cancer screenings.